Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

405 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Prognostic markers of disease activity in Hodgkin's disease.
Martinow AJ, Yuen K, Cooper IA, Matthews JP, Juneja S, Wolf M, Januszewicz H, Prince HM. Martinow AJ, et al. Among authors: prince hm. Leuk Lymphoma. 1998 Apr;29(3-4):383-9. doi: 10.3109/10428199809068574. Leuk Lymphoma. 1998. PMID: 9684935
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM, Bashford J, Wall D, Rischin D, Parker N, Toner GC, Seymour JF, Blakey D, Haylock D, Simmons P, Francis P, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P. Prince HM, et al. Cytotherapy. 2002;4(2):137-45. doi: 10.1080/146532402317381848. Cytotherapy. 2002. PMID: 12006209 Clinical Trial.
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM, Wall D, Rischin D, Toner GC, Seymour JF, Blakey D, Haylock D, Simmons P, Wolf M, Januszewicz EH, Westerman D, Richardson G, Scarlett J, Briggs P. Prince HM, et al. Cytotherapy. 2002;4(2):147-55. doi: 10.1080/146532402317381857. Cytotherapy. 2002. PMID: 12006210 Clinical Trial.
405 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page